Human immunodeficiency virus & cardiovascular risk

Indian Journal of Medical Research

Volumn 134, Issue 12, 2011, Pages 898-903

  Barbaro, Giuseppe ^a   Barbarini, Giorgio ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Acquired immunodeficiency syndrome; Cardiovascular disease; Highly active antiretroviral therapy; Human immunodeficiency virus; Lipodystrophy syndrome

Indexed keywords

ABACAVIR; DIDANOSINE; INDINAVIR; LOPINAVIR PLUS RITONAVIR; PROTEINASE INHIBITOR; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BLOOD CLOTTING DISORDER; CARDIOMYOPATHY; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; ENDOCARDITIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPOSI SARCOMA; NONHODGKIN LYMPHOMA; NONHUMAN; PERICARDIAL EFFUSION; PERIPHERAL VASCULAR DISEASE; PULMONARY HYPERTENSION; REVIEW; VASCULITIS; VIRUS INFECTION;

EID: 84856565836     PISSN: 09715916     EISSN: None     Source Type: Journal    
DOI: 10.4103/0971-5916.92634     Document Type: Review

References (51)

1. Barbarini G, Barbaro G. Incidence of the involvement of the cardiovascular system in HIV infection. AIDS 2003; 17: S46-S50.
2. Barbaro G, Di Lorenzo G, Grisorio B, Barbarini G and the Gruppo Italiano per lo Studio Cardiologico dei pazienti affetti da AIDS Investigators. Cardiac involvement in the acquired immunodeficiency syndrome. A multicenter clinicalpathological study. AIDS Res Hum Retroviruses 1998; 14: 1071-7.
3. Lewis W, Grupp IL, Grupp G, Hoit B, Morris R, Samarel AM, et al. Cardiac dysfunction in the HIV-1 transgenic mouse treated with zidovudine. Lab Invest 2000; 80: 187-97.
4. Bristow MR, Mason JW, Billingham ME, Daniels JR. Doxorubicin cardiomyopathy: evaluation by phonocardiography, endomyocardial biopsy and cardiac catheterization. Ann Intern Med 1978; 88: 168-75.
5. Brown DL, Sather S, Cheitlin MD. Reversible cardiac dysfunction associated with foscarnet therapy for cytomegalovirus esophagitis in an AIDS patient. Am Heart J 1993; 125: 1439-41.
6. Bijl M, Dieleman JP, Simoons M, Van Der Ende ME. Low prevalence of cardiac abnormalities in an HIV-seropositive population on antiretroviral combination therapy. J AIDS 2001; 27: 318-20.
7. Twagirumukiza M, Nikeramihigo E, Seminega B, Gasakure E, Boccara F, Barbaro G. Prevalence of dilated cardiomyopathy in HIV-infected african patients not receiving HAART: a multicenter, observational, prospective, cohort study in Rwanda. Curr HIV Res 2007; 5: 129-37.
8. Beck MA, Kolbeck PC, Shi Q, Rohr LH, Morris VC, Levander OA. Increased virulence of a human enterovirus (coxackievirus B3) in selenium-deficient mice. J Infect Dis 1994; 170: 351-7.
9. Hoffman M, Lipshultz SE, Miller TL. Malnutrition and cardiac abnormalities in the HIV-infected patients. In: Miller TL, Gorbach S, editors. Nutritional aspects of HIV infection. London: Arnold; 1999. p. 33-9.
10. Nzuobontane D, Blackett KN, Kuaban C. Cardiac involvement in HIV-infected people in Yaounde, Cameroon. Postgrad Med J 2002; 78: 678-81.
11. Ntsekhe M, Hakim J. Impact of human immunodeficiency virus infection on cardiovascular disease in Africa. Circulation 2005; 112: 3602-7.
12. Klatt EC. Cardiovascular Pathology in AIDS. Adv Cardiol 2003; 40: 23-48.
13. B arbaro G. Reviewing the clinical aspects of HIV-associated pulmonary hypertension. J Respir Dis 2004; 25: 289-93.
14. Sitbon O, Gressin V, Speich R, Mcdonald PS, Opravil M, Cooper DA, et al. Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care 2004; 170: 1212-7.
15. Barbaro G, Lucchini A, Pellicelli AM, Grisorio B, Giancaspro G, Barbarini G. Highly active antiretroviral therapy compared with HAART and bosentan in combination in patients with HIV-associated pulmonary hypertension. Heart 2006; 92: 1164-6.
16. Johnson RM, Little JR, Storch GA. Kawasaki-like syndromes associated with human immonodeficiency virus infection. Clin Infect Dis 2001; 32: 1628-34.
17. Johnson RM, Barbarini G, Barbaro G. Kawasaki-like syndromes and other vasculitic syndromes in HIV-infected patients. AIDS 2003; 17 (S1):S77-S82.
18. Shingadia D, Das L, Klein-Gitelman N, Chadwick E. Takayasu's arteritis in a human immunodeficiency virusinfected adolescent. Clin Infect Dis 1999; 29: 458-9.
19. Barbaro G. Vasculitic syndromes in HIV-infected patients. Adv Cardiol 2003; 40: 185-96.
20. B arbaro G, Barbarini G, Pellicelli AM. HIV-associated coronary arteritis in a patient with fatal myocardial infarction. N Engl J Med 2001; 344: 1799-800.
21. Twu C, Liu QN, Popik W, Bukrinsky M, Sayre J, Roberts J, et al. Cardiomyocytes undergo apoptosis in human immunodeficiency virus cardiomyopathy through mitochondrion and death receptor-controlled pathways. Proc Natl Acad Sci USA 2002; 99: 14386-91.
22. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12: F51-F58.
23. Carr A. HIV lipodystrophy: risk factors, pathogenesis, diagnosis and management. AIDS 2003; 17 (S1): S141-8.
24. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 2005; 352: 48-62.
25. Hadigan C, Meigs JB, Rabe J, D'Agostino RB, Wilson PW, Lipinska I, et al. Increased PAI-1 and tPA antigen levels are reduced with metformin therapy in HIV-infected patients with fat redistribution and insulin resistance. J Clin Endocrinol Metab 2001; 86: 939-43.
26. Witz M, Lehmann J, Korzets Z. Acute brachial artery thrombosis as the initial manifestations of human immunodeficiency virus infection. Am J Hematol 2000; 64: 137-9.
27. Sullivan PS, Dworkin MS, Jones JL, Hooper WC. Epidemiology of thrombosis in HIV-infected individuals. The Adult/Adolescent Spectrum of HIV Disease Project. AIDS 2000; 14: 321-4.
28. Miguez-Burbano MJ, Burbano X, Rodriguez A, Lecusay R, Rodriguez N, Shor-Posner G. Development of thrombocytosis in HIV+ drug users: impact of antiretroviral therapy. Platelets 2002; 13: 183-5.
29. Aoun S, Ramos E. Hypertension in the HIV-infected patient. Curr Hyperten Rep 2000; 2: 478-81.
30. National Cholesterol Education Program (NCEP) Expert Panel on Detection EaToHBCiAATPI. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-421.
31. Gazzaruso C, Bruno R, Garzaniti A, Giordanetti S, Fratino P, Sacchi P, et al. Hypertension among HIV patients: prevalence and relationship to insulin resistance and metabolic syndrome. J Hypertens 2003; 21: 1377-82.
32. Crane H, Van Rompaey S, Kitahata M. Antiretroviral medications associated with elevated blood pressure among patients receiving highly active antiretroviral therapy. AIDS 2006; 20: 1019-26.
33. Sattler FR, Qian D, Louie S, Johnson D, Briggs W, DeQuattro V, et al. Elevated blood pressure in subjects with lipodystrophy. AIDS 2001; 15: 2001-10.
34. Roling J, Schmid H, Fischereder M, Draenert R, Goebel FD. HIV-associated renal diseases and highly active antiretriviral therapy-induced nephropathy. Clin Infect Dis 2006; 42: 1488-95.
35. Maggi P, Serio G, Epifani G, Fiorentino G, Saracino A, Fico C, et al. Premature lesions of the carotid vessels in HIV-1-infected patients treated with protease inhibitors. AIDS 2000; 14: F123-8.
36. Depairon M, Chessex S, Sudre P, Rodondi N, Doser N, Chave JP, et al. Premature atherosclerosis in HIV-infected individuals: focus on protease inhibitor therapy. AIDS 2001; 15: 329-34.
37. Hsue PY, Lo JC, Franklin A, Bolger AF, Martin JN, Deeks SG, et al. Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation 2004; 109: 1603-8.
38. Currier JS, Kendall MA, Zackin R, Henry WK, Alston-Smith B, Torriani F, et al. Carotid artery intima-media thickness and HIV infection: traditional risk factors overshadow impact of protease inhibitor exposure. AIDS 2005; 19: 927-33.
39. Thiebaut R, Aurillac-Lavignole V, Bonnet F, Ibrahim N, Cipriano C, Neau D, et al. Change in atherosclerosis progression in HIV-infected patients: ANRS Aquitane Cohort, 1999-2004. AIDS 2005; 19: 729-31.
40. Barbaro G, Di Lorenzo G, Cirelli A, Grisorio B, Lucchini A, Hazra C, et al. An open-label, prospective, observational study of the incidence of coronary artery disease in patients with HIV receiving highly active antiretroviral therapy. Clin Ther 2003; 25: 2405-18.
41. B ozzette SA, Ake CF, Tam HK, Chang SW, Louis TA. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 2003; 348: 702-10.
42. Holmberg SD, Moorman AC, Williamson JM, Tong TC, Ward DJ, Wood KC, et al. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet 2002; 360: 1747-8.
43. Friis-Moller N, Weber R, Reiss P, Thiebaut R, Kirk O, D'Arminio Monforte A, et al. Cardiovascular risk factors in HIV patients-association with antiretroviral therapy. Results from DAD study. AIDS 2003; 17: 1179-93.
44. Mary-Krause M, Cotte L, Simon A, Partisani M, Costagliola D and the Clinical Epidemiology Group from the French Hospital Database. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 2003; 17: 2479-86.
45. Worm SW, Sabin C, Weber R, Reiss P, El-Sadr W, Dabis F, et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major classes: the data collection on adverse events of anti-HIV drugs (DAD) study. J Infect Dis 2010; 20: 318-30.
46. HIV Medicine Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trial Groups. Guidelines for the Evaluation and Management of Dyslipidemia in Human Immunodeficiency Virus (HIV)-Infected Adults Receiving Antiretroviral Therapy: Recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trial Groups. Clin Infect Dis 2004; 37: 613-27.
47. Volberding P, Murphy R, Barbaro G, Barbarini G, Bruno R, Cirelli A, et al. The Pavia Consensus Statement. AIDS 2003; 17 (S1): S170-9.
48. Barbaro G, Iacobellis G. Metabolic syndrome associated with HIV and highly active antiretroviral therapy. Curr Diab Rep 2009; 9: 37-42.
49. Iacobellis G, Sharma AM, Pellicelli AM, Grisorio B, Barbarini G, Barbaro G. Epicardial adipose tissue is related to carotid intima-media thickness and visceral adiposity in HIV-infected patients with highly active antiretroviral therapy-associated metabolic syndrome. Curr HIV Res 2007; 5: 275-9.
50. Iacobellis G, Pellicelli AM, Sharma AM, Grisorio B, Barbarini G, Barbaro G. Relation of subepicardial adipose tissue to carotid intima-media thickness in patients with human immunodeficiency virus. Am J Cardiol 2007; 99: 1470-2.
51. Iacobellis G, Pellicelli AM, Grisorio B, Barbarini G, Leonetti F, Sharma AM, et al. Relation of epicardial fat and alanine aminotransferase in subjects with increased visceral fat. Obesity 2008; 16: 179-83.